GIORGETTI, GIULIA
 Distribuzione geografica
Continente #
EU - Europa 347
AS - Asia 118
NA - Nord America 47
SA - Sud America 10
AF - Africa 3
Totale 525
Nazione #
IT - Italia 330
SG - Singapore 53
US - Stati Uniti d'America 42
VN - Vietnam 27
CN - Cina 26
BR - Brasile 6
HK - Hong Kong 6
DE - Germania 5
FR - Francia 4
CA - Canada 3
AR - Argentina 2
FI - Finlandia 2
GB - Regno Unito 2
ID - Indonesia 2
AT - Austria 1
BO - Bolivia 1
EC - Ecuador 1
EG - Egitto 1
HN - Honduras 1
IQ - Iraq 1
JP - Giappone 1
LB - Libano 1
LT - Lituania 1
MG - Madagascar 1
MX - Messico 1
NL - Olanda 1
TR - Turchia 1
UA - Ucraina 1
ZA - Sudafrica 1
Totale 525
Città #
Genoa 296
Singapore 30
Ho Chi Minh City 14
Vado Ligure 14
Council Bluffs 6
Hong Kong 6
Rapallo 6
San Jose 6
Beijing 4
Frankfurt am Main 4
Hanoi 3
Lauterbourg 3
Santa Clara 3
Shenzhen 3
Buffalo 2
Haiphong 2
Helsinki 2
New York 2
Amsterdam 1
Antakya 1
Antananarivo 1
Ashburn 1
Biên Hòa 1
Brantford 1
Buenos Aires 1
Cairo 1
Chicago 1
Cuenca 1
Depok 1
Durban 1
Formosa 1
Glace Bay 1
Houston 1
Hải Dương 1
Karbala 1
Kyiv 1
La Paz 1
London 1
Los Angeles 1
Nuremberg 1
Orem 1
Osasco 1
Paulista 1
Pimenta Bueno 1
Poplar 1
Pulversheim 1
Quảng Nam Province 1
Rome 1
Salt Lake City 1
Saquarema 1
Schiavon 1
Sidon 1
São Paulo 1
Thái Nguyên 1
Tokyo 1
Turin 1
Ubá 1
Ân Thi 1
Totale 446
Nome #
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 164
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA 121
CD56-OVEREXPRESSING MYELOMA CELLS ARE MORE VULNERABLE TO NAD+ EXHAUSTING STRATEGIES DUE TO DEPENDENCY ON CD38 ENZYMATIC ACTIVITY 76
Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies 57
The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS 45
A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma 30
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies 28
PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma 19
Totale 540
Categoria #
all - tutte 1.424
article - articoli 886
book - libri 0
conference - conferenze 409
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.719


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202310 0 0 0 0 0 0 0 2 0 3 3 2
2023/202432 1 3 7 7 4 2 1 4 1 0 0 2
2024/2025139 3 3 3 3 3 12 6 16 6 22 25 37
2025/2026359 45 18 48 54 47 22 33 27 33 32 0 0
Totale 540